Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Cash from Investing Activities (2016 - 2025)

Integra Lifesciences Holdings' Cash from Investing Activities history spans 17 years, with the latest figure at -$34.9 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 721.53% year-over-year to -$34.9 million; the TTM value through Dec 2025 reached -$108.1 million, up 72.35%, while the annual FY2025 figure was -$108.1 million, 72.35% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$34.9 million at Integra Lifesciences Holdings, down from -$15.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $14.8 million in Q3 2022 and bottomed at -$322.2 million in Q2 2024.
  • The 5-year median for Cash from Investing Activities is -$15.6 million (2023), against an average of -$40.7 million.
  • The largest annual shift saw Cash from Investing Activities soared 274.69% in 2022 before it plummeted 1972.28% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at -$27.5 million in 2021, then tumbled by 99.45% to -$54.8 million in 2022, then dropped by 4.39% to -$57.2 million in 2023, then soared by 92.58% to -$4.2 million in 2024, then tumbled by 721.53% to -$34.9 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Cash from Investing Activities are -$34.9 million (Q4 2025), -$15.6 million (Q3 2025), and -$21.6 million (Q2 2025).